| Budget Amount *help |
¥3,200,000 (Direct Cost: ¥3,200,000)
Fiscal Year 1999: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1998: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 1997: ¥1,400,000 (Direct Cost: ¥1,400,000)
|
|---|
| Research Abstract |
To elucidate the clinical usefulness of serum matrix metalloproteinase (MMP)-1, MMP-2, MMP-3 and MMP-9 in chronic liver disease and hepatocellular carcinoma, we measured these enzyme concentrations in serum and liver, and compared the results with clinicopathological findings.
(1)Serum MMP-1 concentration decreased during histological progression of chronic hepatitis. The serum MMP-1 test was useful clinically to differentiate active and inactive types of hepatitis in patients with chronic viral hepatitis.
(2)The serum MMP-2 concentration refects mainly the amount of proMMP-2 complexed with TIMP-2. The serum MMP-2 level was markedly increased in cirrhotic patients, and may be explained by an overproduction in the cirrhotic liver. In the clinical state, the measurement of serum MMP-2 was as useful a test for diagnosing liver cirrhosis as the serum hyaluronan test.
(3)The plasma MMP-9 level, as well as the MMP-2 level, was significantly increased in cirrhotic patients, probably due to overproduction in the cirrhotic liver. However, the plasma MMP-9 test was inferior to the plasma MMP-2 test for the diagnosis of cirrhosis.
(4)The serum MMP-3 concentration was about 2-fold higher in the males than in the females, and 55% lower in chronic hepatitis, 53% lower in liver cirrhosis and 46% lower in hepatocellular carcinoma. The MMP-3 concentration in the cirrhotic liver was quite similar to that in the non-cirrhotic liver. The measurement of serum MMP-3 was of little use for assessing fibrolysis in chronically diseased livers.
|
